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Abstract
The inflammatory response after a spinal cord injury (SCI) is a secondary 
mechanism of damage, this involves alterations at the local and systemic level, 
and it is mediated by cytokine participation that takes part actively. The excessive 
inflammatory response causes an autoreactive response that targets against com-
ponents of the nervous tissue; this response lengthens the inflammatory process 
initiated during the acute phase. The participation of immune cells in acute phases 
is characterized by the arrival of neutrophils, macrophages, and microglia, as well 
as T lymphocytes, which express their peaks on different days post-injury (1st, 
3rd, and 11th respectively). The chronic phase of the injury begins 14 days after it 
occurred, reaching its highest point at 60 days, and can still be detected the fol-
lowing 180 days. One of the outcomes of the inflammatory process and cytokine 
synthesis is the generation of glial scar. In this chapter, we will review the different 
cytokine mechanisms involved in the formation of glial scar in acute and chronic 
phases, as well as the modulating treatments of glial scar.
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1. Introduction
Spinal cord injury (SCI) causes catastrophic damaged to patients, and the 
incidence is getting higher each year. Most of them are occasioned by physical 
trauma from sports injuries, car accidents, falls, and more [1, 2]. This life-changing 
neurological condition also comes with socioeconomic implications for patients and 
their caregivers, besides the functional and sensitive consequences that are largely 
determined by the level and completeness of the injury [1, 3].
After SCI, the acute and focal inflammation triggers a multicellular and multi-
functional complex response which induces resident and infiltrating cells to form 
the glial scar (GS) at the site of the lesion [3]. The GS is a complicated phenomenon 
which has been considered as one of the main causes of limited regenerative 
capacity by inhibiting axonal regeneration and preventing functional recovery 
[4]. It has been proven that the GS creates both a physical barrier for neural repair 
as well as a chemical inhibition by the secretion of inhibitory extracellular matrix 
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molecules [5]. At the present time, finding an effective treatment has shown to 
be challenging due to the lack of complete understanding about the multifacto-
rial pathophysiology of SCI. Current medical treatment is confined to surgical 
procedures and anti-inflammatory drugs which aim to reduce the damage caused 
by the continuous inflammatory reactions and therefore increase the locomotor 
recovery. More importantly, recent studies have demonstrated that the GS can be 
both favorable or prejudicial depending on the evolution time of the SCI, being able 
to participate in tissue repair and functional recovery during the acute phase but 
later on establishing a recovery plateau due to the inhibition of axonal regeneration 
during the chronic phase [6, 7]. Therefore, in recent years there has been an increas-
ing interest in developing new therapies that can modulate the immunological 
responses involved in the GS formation. Although there are many drugs that have 
been identified as potential treatments for SCI, there is currently no therapy that 
can effectively restore the neural function that is lost during this pathology. The 
purpose of this chapter is to describe the importance of cytokines in the immuno-
logical processes of GS formation as well novel therapies that could serve as poten-
tial treatments of SCI.
2. Inflammation in traumatic central nervous system
Disorders in the homeostasis of the central nervous system (CNS) just as infec-
tion, trauma, ischemia, neurodegenerative diseases, and disturbances in general 
induce the beginning of neuroinflammatory responses that can be considered to 
consist principally of innate immune mechanisms [8, 9].
Inflammation is the way the human body acts in response to situations such as 
injury and infection. This mechanism involves several processes of the somatosen-
sory, autonomic, immune, and vascular systems and more [10].
The immune and nervous system are capable of regulating physiological 
homeostasis and defending against infection and injury through inflammation. 
Both systems have improved many features for the recognition of alterations in the 
changing microenvironment to facilitate the protective responses. Although cells in 
each system (neurons and immune cells) have many differences, they can inter-
act and communicate together to make a functional cooperation for the integral 
homeostasis [11].
Neuroinflammation is a localized inflammation in both CNS and peripheral 
nervous system (PNS), despite being distinct from the inflammation in peripheral 
tissues. There is also upregulation of several pro-inflammatory cytokines like IL-1β, 
IL-6, TNFα, and chemokines that affect the integrity of the blood brain barrier 
(BBB) resulting in local and systemic immune responses [9, 10, 12].
During these events, neural control plays an important role due to the fact that 
many immune molecules are detected by sensory neurons, which lead the system 
to generate immunoregulatory responses [13]. In general, the nervous system 
integrates biological functions to restore homeostatic function with the use of 
neurotransmitters and other regulatory molecules [11].
On the other hand, there are other cell types involved in the response, such 
as microglial and astrocytes. Microglial cells are made to deal with the harmful 
effects involving the activation of astrocytes, which are capable of modulating 
the activity of other immunocompetent cells in the site of the injury and also 
have an active role in the synaptic elimination, regeneration, cell elongation, and 
repair [8, 14, 15]. Many studies have reported that astrocytes participate in axonal 
regeneration by providing growth substrates and guidance structures [16]. They 
are also required in CNS repair, especially in the acute phase after injury but not 
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in the chronic phase, reducing GS formation and exacerbating the magnitude and 
duration of inflammatory activation [17, 18].
Nevertheless, it has been confirmed that inflammatory mechanisms contribute 
both to cell damage and tissue remodeling [12]. They are involved in reactive 
plasticity modulation of neuronal populations in different types of brain injuries, 
as well as in microglial cells and astrocytes, since they can activate and promote 
recovery and repair the neural circuits [8].
Owing to the events explained before, neuroinflammation is taken into account 
as an important manipulable aspect of injury in animal and human studies to 
develop immunomodulatory therapies because it can be detrimental or beneficial; 
however, it is necessary to understand the processes in a better way [19].
2.1 Inflammatory response after spinal cord injury
In the SCI there are two phases of the pathology: the primary one which consists 
in the initial accident-induced damage that can result from the compression of the 
spinal cord (SC), stretching of the nervous tissue, or disruption of local blood sup-
ply and the secondary one, which is characterized by the damage caused by inflam-
mation and other biological mechanisms. These events can start at the moment of 
the injury and go on for days, and even weeks, after the event [2, 20] (see Figure 1).
Inflammatory microenvironment after SCI involves activated microglia, 
astrocytes, and infiltrating macrophages that play a role in the development of the 
secondary injury, and it is the major target to combat SCI [1, 2]. Then, this environ-
ment following SCI is mediated by the activation of microglia and astrocytes and 
infiltrating macrophages that greatly contribute to the progression of secondary 
injury that is a compilation of complex events derived from the initial trauma. Some 
of the mechanisms in its pathogenesis includes neurodegeneration, gliosis, and 
apoptosis in nearby intact neural tissues [21–25]. Effective restraint of secondary 
injury is essential to minimize neurodegeneration and to improve significantly 
functional recovery [1].
It is important to know that a traumatic injury in the CNS begins with the 
disruption of the BBB and blood-spinal barrier (BSB), followed by the arrival of 
several cells and molecules of the immune system with the possibility of aggravat-
ing the situation, affecting subsequent events such as repair and regeneration [26].  
Figure 1. 
Inflammatory response after spinal cord injury.
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The inflammatory microenvironment after SCI involves activated microglia, 
astrocytes, and infiltrating macrophages that play a role in the development of the 
secondary injury, and it is the major target to combat SCI.
It has been demonstrated that there is a multiphasic response during the inflam-
mation processes after SCI and a huge interaction between central and peripheral 
cellular and soluble components, which are influenced by some factors like patient 
age, sex, mechanism and degree of injury, therapeutic interventions, and genetic 
variability [9, 26].
In a study made by Beck et al. [26], they established two types of cellular inflam-
mation phases. The early phase includes principally the infiltration of neutrophils 
which are polymorphonuclear leucocytes (PMNs), macrophages, and microglia, 
which inhibit recovery of the brain and SCI after the traumatic event. It was dis-
covered that neutrophils are peaking 1 day of post-injury, macrophages/microglia 
7 days of post-injury, and T cells 9 days of post-injury. The late phase was detected 
after 14 days of post-injury with its peak after 60 days of post-injury, and it also 
remained detectable throughout the 180 days of post-injury for all three cell types 
mentioned before. Moreover, the inhibition of the C5a-mediated inflammation after 
14 days of injury reduced the locomotor recovery and myelination of the SC in the 
damaged site, suggesting that the late phase involves a restorative function [26].
Following this line, after the damage to the microvasculature, the presence of 
progressive edema and proapoptotic signaling begins. All of these events promote 
thrombosis and microvessel spasms causing hypoxia. Therefore, a relevant aspect 
to mention is that astrocytes are the first to act in the injury site, contributing to 
the formation of the GS, as well as preventing neurons to grow and heal [1, 20]. In 
the same way, neutrophils and macrophages are recruited from the periphery to the 
injured area, and, together with reactive astrocytes, microglia/macrophages will 
also contribute to the formation of a regeneration-inhibiting GS [27].
3. Cytokines and acute glial scar formation after spinal cord injury
In the early phase, the formation of GS has a protective function, isolating 
potentially dangerous molecules of the rest of healthy tissue and controlling the 
spread of damage [28]. Accordingly with this, GS is considered as a mechanism of 
protection, developed by the organism against injuries that affect the CNS.
Overall, the GS is composed of two parts, the fibrotic and the glial. The fibrotic 
scar occupies the core of the injury with deposits of collagen matrix and is mainly 
composed of invading fibroblasts derived from meningeal and perivascular cells 
[29, 30]. The GS occupies the peripheral zone of the lesion and is composed mainly 
of astrocytes due to its evolution from a dynamic process known as reactive astro-
gliosis [30]. The glial limiting membrane is a specialized structure that is located 
close to the outer layer of the fibrotic scar and marks the division between these two 
parts [31]. Besides fibroblasts and astrocytes, the GS is also formed by NG2 + oligo-
dendrocyte precursor cells (OPCs), microglia, pericytes, and ependymal cells [32].
A phenomenon that occurs simultaneously with the destruction of neuronal com-
ponents is the activation of an inflammatory response characterized at first moment 
by the release of chemokines by endothelial cells and microglia cells [33]. These 
chemokines induce the migration of peripheral immunological cells to the affected 
tissue and promote the posterior establishment of inflammatory response [34]. The 
migration of macrophages and lymphocytes besides the activation of microglial cells 
is joined to the deficiency to control an inflammatory process in the CNS, thereby 
contributing with a destructive immunological response [35]. Both resident and 
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infiltrating cells contribute to the GS formation, and the main characteristic of the 
inflammatory response at this time point is the sustained production of free radicals 
due to the continuous synthesis of pro-inflammatory cytokines like TNF-α, IL-1β, 
INF-γ, and enzymes that activate glial cells or disrupt the BSB [34, 36]. Moreover, 
activated macrophages produce and secrete matrix metalloproteinases (MMPs) to 
furtherly disrupt the BSB and increase vascular permeability [37].
Another phenomenon observed is the activation of inflammasome. The damage 
of cell membranes permits the release of molecules of ATP and the efflux of K+, 
stimulating the activation of the inflammasome and inducing the production of 
the pro-inflammatory cytokines, IL-1β and IL-18, which these cytokines have been 
related with neurodegenerative process [38]. Furthermore, studies in vitro have 
shown the direct relation of IL-1β with the overexpression of glial fibrillary acidic 
protein (GFAP) on astrocytes; for this reason the activation of inflammasome is a 
key factor involved in the formation and maturation of GS [39].
Astrocyte is a specific cell residing only in the CNS that maintains the homeosta-
sis, conforms the BBB, and keeps the concentration of ions and neurotransmitters 
to regulate the activity in neuronal synapsis [40].
Reactive astrocytes (RAs) possess surface receptors for different cytokines just 
like the cells of the immune system, making them a target for products derived 
from the inflammatory environment. The pro-inflammatory cytokines induce 
the upregulation of inflammatory genes on astrocytes and the posterior secretion 
of various chemokines, including CXCL1, CCL2, CCL3, CCL4, and CXCL12, and 
cytokines like IL-1, transforming growth factor β (TGFβ), TNF-α, and INFγ. For 
example, INFγ interacts to modulate several facets of the gliotic response, and such 
interactions with growth factors may be important in creating the biochemical and 
physical properties of the GS; for this reason this cytokine is responsible for failed 
neuronal regeneration after SCI [41]. In this way, the astrocytes can contribute 
with the presence of a constant inflammatory response, affecting themselves and 
influencing other cell populations related with the formation of GS [41, 42].
Fibroblasts secrete extracellular matrix (ECM) components which include the 
chondroitin sulfate proteoglycans (CSPGs) family (neurocan, versican, brevican, 
phosphocan, and NG2) which is mainly secreted by astrocytes as well as fibronec-
tin, collagen, and laminin which are produced by fibroblasts [36, 43]. Altogether, 
they contribute to the formation of GS and participate in developing its characteris-
tic impermeability and the expression of molecules that impede the anatomical and 
functional restoration after the lesion [32, 44]. Fibroblasts also possess cytokine 
receptors on their surface which respond to high concentrations of pro-inflamma-
tory cytokines and stimulate the activation of enzymatic machinery synthesized 
ECM protein. The inhibition of pericytes and fibroblasts by the application of 
different therapeutical strategies reduce the size and consolidation of GS, showing 
the importance of these types of cells in the GS formation. Of great importance is 
the presence of specific receptor for TGFβ on fibroblasts; the stimulation with this 
molecule facilitates the synthesis and release of collagen type IV [45].
Generally speaking, after an injury to the CNS, there is a sequential pheno-
typic change in astrocytes called reactive astrogliosis, where naïve astrocytes 
(NAs) are transformed to RAs which eventually become scar-forming astro-
cytes (SAs) that can inhibit axonal regeneration and functional recovery [7]. 
Astrocytes are the most abundant glial cells within the CNS, and although they 
are not part of the immune system, they play a crucial role in the pathophysiology 
of the GS formation [36].
Furthermore, RAs substantially upregulate their expression of GFAP, inter-
mediate filaments, nestin, and vimentin and mobilize to the center of the injury 
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to form a mesh-like structure of interlaced filamentous structures [46]. A high 
concentration of pro-inflammatory cytokines induces upregulation of GFAP on 
astrocytes and the development of hypertrophic prolongation. A certain study 
showed that genetically modified mice with deficiency of vimentin and GFAP pro-
duced a less dense GS which frequently conducted to constant bleeding, suggesting 
that vimentin and GFAP are part of the main cytoskeletal intermediate filaments 
that form the GS [47].
This astrocytic migration secludes inflammatory cells from the surrounding 
intact tissues and minimize the extension of secondary damage after CNS injury 
leading to tissue repair and functional improvement during the acute phase of GS 
formation [7, 48, 49]. In addition, the hemorrhagic flow into the CNS due to the 
rupture of the BBB exposes scar-forming cells to factors in plasma such as fibrino-
gen which has been proven to induce the expression of CSPGs in astrocytes through 
TGFβ/Smad2 signaling pathway [50].
Besides, in the acute phase of the GS formation, the overexpression of CSPGs 
(neurocan, versican, brevican, phosphocan, and NG2+) plays a beneficial role by 
modulating the inflammatory activity of resident microglia as well as the infiltra-
tion of monocytes through the CD44 receptor [51].
Moreover, to the featured RAs, the GS formation also requires the activation 
of ependymal cells, NG2+-expressing glia (including OPCs), meningeal- and 
vascular-derived fibroblasts, pericytes, and macrophages surrounding the injury 
area [52]. More importantly, some of these previously mentioned cells have the 
capacity to switch their phenotypes and become RAs to furtherly contribute in 
the GS formation [53]. Furthermore, there are several molecular mechanisms that 
contribute to the formation of the GS such as the upregulation of bone morpho-
genetic proteins (BMPs), MMPs, epidermal growth factor receptor (EGFR), eph/
ephrins, TGFβ, and signal transducer and activator of transcription and inter-
leukin (STAT/IL) family (STAT3) [30, 54, 55]. The upregulation of BMP-4 has 
shown to promote astrocyte differentiation and to inhibit the production of oligo-
dendrocytes and neurons [56]. In addition, the MMP family is involved in the 
ECM remodeling, and therefore, they are structurally and temporally involved 
in the GS formation [57]. The limitation of the extent of the GS was seen with 
the suppression of MMP-2 in mice, and MMP-9 has proven to be involved in the 
augmented migration of RAs to the injury site, therefore facilitating GS forma-
tion [58]. EGFR is upregulated in astrocytes following damage to the SC, leading 
to the activation of the Rheb-mToR signaling pathway which induces astrocytes 
to migrate and suffer hypertrophy to furtherly form the GS [59]. Moreover, 
EGFR ligands, such as transforming growth factor-alpha (TGF-alpha) and EGF, 
contribute to the formation of the GS by inducing astrocytes to secrete CSGPs 
[60]. In addition, TGFβ expression is upregulated immediately after SCI. It 
promotes the formation of the GS by simultaneously stimulating monocyte and 
lymphocyte activity as well as inducing the production and deposition of new 
ECM proteins (collagen, fibronectin, and proteoglycans) [61, 62]. The manipula-
tion of TGFβ signaling in the injured CNS modulates the formation of the fibrotic 
scar in the lesion site. The administration of TGFβ1 to the injured CNS increases 
the deposition of ECMs in the lesion site [63, 64], while antibodies to TGFβ1 and 
TGFβ2 and the endogenous TGFβ inhibitor decorin, a small leucine-rich CSPG, 
conversely reduce the size of GS [64], which proposes the involvement of TGFβs 
in the formation of GS. In addition, RAs release TNF-α to inhibit oligodendro-
cyte progenitor cell (OPG) survival and prevent them from differentiating into 
mature oligodendrocytes, suggesting a mechanism for the failure of remyelin-
ation after SCI [65].
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4. Modifications of the glial scar
RAs have been traditionally considered to be a unidirectional and irreversible 
process; however, recent studies have proven to inhibit its progress and even 
revert the astrocyte’s phenotype according to environmental cues [48, 49]. Over 
the past few years, there has been an increasing interest in modulating the GS 
formation; nevertheless, there has been a wide spectrum of results mainly due 
to the fact that the GS has many components and there are many different types 
of therapy strategies. Inclusive, recent studies have shown that the attenuation 
of RAs to prevent GS formation has resulted in a worse outcome in SCI and 
limited functional recovery [6, 7]. In transgenic mice where STAT3 selectively 
suppressed RAs showed reduced migration to the lesion epicenter, leading to 
an extensive area of injury with uncontrolled inflammatory cell filtration and 
limited functional recovery [7]. Another study showed a pronounced reduction 
of glial scarring in animals with conditional knockdown of STAT3, suggesting 
that this molecule is one of the most important factors involved in the formation 
of the GS [62]. A wide spectrum of molecules such as type I and II interferons 
and cytokines, growth factors including EGF, platelet-derived growth factor, 
IL-6, leukemia inhibitory factor, and ciliary neurotrophic factor (CNF) is able 
to activate STAT3 in order to cause variations in RAs and elicit GS formation 
[66, 67]. Similarly, a recent study used HSV1tk/GCV (a suicide system gene) 
to selectively kill proliferating RAs in SCI to avoid GS formation, resulting in a 
widespread infiltration of inflammatory cells and continuous involvement of 
healthy tissue surrounding the epicenter of the lesion as well as decreased neu-
ronal survival and decreased locomotor recovery [5]. These findings furtherly 
support that reactive astrogliosis in acute-subacute phases plays beneficial roles 
in acute wound healing, remodeling processes, and isolating the injury to prevent 
the spread of cytotoxic molecules and inflammatory cells into the surrounding 
tissue [4, 5].
Even though GS formation in acute phases has proven to have beneficial effects, 
its evolution and persistence in chronic stages of the injury have shown to become a 
strong inhibitor for SC regeneration [3]. Therefore, there has been some attempts in 
regulating the chronic phase of the GS to improve axonal outgrowth.
5. Cytokines and chronic glial scar formation after spinal cord injury
Through the years, it became clear that both the scar tissue and the immune 
system play important beneficial roles in axonal regeneration and healing of the 
CNS [68].
As mentioned before, SCI results in the disruption of the BBB, and the BSB 
increased inflammatory reactions such as the activation of the microglia and the 
production of various cytokines and augmented the activation of TGFβ and Smad2 
signaling pathways [49]. The inflammatory microenvironment presented after the 
insult continues in most of the cases until the chronic phase [34].
Acute GS formation restricts inflammation and preserves neural tissue [28, 46, 69]. 
Nonetheless, at the chronic phase (>14 days after the injury in mice), RAs progressively 
transform into SAs that form astrocytic scars which compose the main impediment 
for axonal regeneration and functional recovery in the chronic phase of SCI [70, 71]. It 
has been suggested that after inflammation has resolved, chronic GS is expendable and 
detrimental because it continually prevents axon regeneration [6]. For this reason, it is 
necessary in chronic phases to inhibit, modulate, or remove the mature GS.
Cytokines
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Certain factors present during the acute formation of the glial scar are also active 
during its chronic formation. The genetic suppression of BMPR1b (a subtype of the 
BMP type 1 receptor) resulted in the weakening of the GS in chronic stages of SCI, 
suggesting that BMPs play an important role in the acute formation of the GS as 
well as in its stabilization through the chronic stage [72].
Although the expression of CSPGs during acute glial scar formation participates 
in reducing the damage extent, the prolonged exposure of CSPGs is prejudicial for 
functional recovery for they are well-known to be the main inhibitors of GS axonal 
regeneration, sprouting, and remyelination during the chronic phase of SCI [3, 73]. 
The posterior formation of the GS traps on its core of GS, where they reside contrib-
uting with the chronic presence of an inflammatory response. The continual synthesis 
of pro-inflammatory cytokines like TNFα, IL1β, and INFγ promotes the aggregation 
of new elements and the modification of GS [74].
This is the main reason why astrogliosis may cause both beneficial and detri-
mental effects depending on its dynamic features and on its time course [50, 69]. 
Cytokines behave in a similar way. In the early stages of GS formation, pro-inflam-
matory cytokines such as TNF-α, IL-1β, and INF-γ help by recruiting and activating 
microglial cells, astrocytes, and other peripheral immunological cells to the injury 
site to prevent the extension of the injury [33, 35]. However, other acute-secreted 
cytokines such as IL-1β and IL-18 have been associated with neurodegenerative 
processes and activation of the inflammasome [37, 38]. On the other hand, during 
the chronic formation of the GS, cytokines contribute to impede axonal regenera-
tion and functional recovery. Overall, cytokines may present both beneficial and 
detrimental effects depending on the stage of GS formation and depending on the 
process in which they are involved. Certain cytokines which are present in early 
stages and may present beneficial effects by increasing the production of CSPGs 
may become prejudicial as time progresses. Current pharmacological treatments 
Cytokine Scar glial effect References
TGFβ Induces the expression of CSPGs in astrocyte
Facilitates the synthesis and release of collagen type IV in fibroblast
Increases the deposition of ECMs in the lesion site
Inhibits the generation of TGFβ1, TGFβ2, and SOX-9 and as a result there is 
a decreased deposition of CSPG
[60]
[45]
[63, 64]
[28]
IL-1β Increases overexpression of GFAP on astrocytes and maturation of GS [39]
TNFα RAs release TNF-α to inhibit OPCs survival and prevent them from 
differentiating into mature oligodendrocytes, suggesting a mechanism for 
the failure of remyelination after SCI
Reduces the expression of GFAP through anti-inflammatory processes and 
helps to suppress reactive gliosis
[27]
INFγ Promotes SG formation and modulates ECM which helps that the 
interactions with growth factors may be important in creating modification 
in the GS
[36]
IL-4 and 
IL13
IL-4 and 
IL-10
Transplantation with BMSCs was associated with significant increases 
in IL-4 and IL-13; these changes were associated with less scar tissue 
formation
INDP in combination with scar removal and DPY reduces pro-
inflammatory cytokines in chronic phase
[79]
[78]
IL-10 Activates beneficial M2 macrophages which were found to regulate scar 
resolution
[18]
Table 1. 
Main cytokines involve in scar glial formation.
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depend on cytokines to establish their mechanism of action and should be focused 
to develop further pharmacological strategies.
The majority of SCI patients are those with lesions who may benefit insufficiently 
from therapeutic treatments designed for application in the chronic stage and focused 
on cytokines and other immunological processes. However, compared to treatments 
of acute experimental SCI, the efficacy of therapies promoting axonal regeneration 
seems impaired in chronic models. Therefore, GS formation can be improved if we 
combine treatments like stem cell transplants [75], iron chelators [76–78], and matrix 
biocompatible [16, 78]. Table 1 summarizes some GS effects exerted by cytokines.
6. Modulate, inhibit, or remove glial scar as therapeutic tool
In this section we will review some modulating treatments of the GS. That 
should be able to counteract posttraumatic factors of inhibitory growth and pro-
mote axonal and tissue recovery.
6.1 Anti-inflammatory therapy
In contrast with the pro-inflammatory cytokines produced after the injury, the 
application of anti-inflammatory therapies like the treatment with doses of methyl-
prednisolone (MP) after the injury avoids the formation of the GS. The application 
of MP is helpful to reduce the expression of GFAP and reduce the deposition of 
CSPG and avoid the formation of the GS [80].
Combination therapy using MP and tranilast after SCI in rats significantly 
reduced posttraumatic SC edema and neutrophil infiltration and improved func-
tional recovery better than single individual therapies, and it also significantly 
reduced the amount of GFAP expression at the injury site [81].
Therapies that induce elevated concentrations of IL-10, a well-known anti-
inflammatory cytokine, reduce in an important way the presence of CSPG on GS 
[82]. Astrocytes also express the transcription nuclear factor (NF-kB). The selective 
inhibition of NF-kB induces a better neurological outcome and a reduction in size 
of the GS. In addition, the interference of NF-kB induces the reduction of pro-
inflammatory cytokines, chemokines, and secretion of CSPG [83].
Curcinum is a phytochemical compound that has an anti-inflammatory effect. 
This molecule inhibits pro-inflammatory cytokines (TNFα and IL-1β), which contrib-
ute to reduce the expression of GFAP through anti-inflammatory processes and help 
to suppress reactive gliosis [26]. Previous studies have also demonstrated to inhibit the 
generation of TGFβ1, TGFβ2, and SOX-9; as a result, there is a decreased deposition of 
CSPG, causing the inhibition of TGFβ and transcription factors. There is also evidence 
that curcinum reduces the amount of nestin and GFAP around de SCI, suggesting that 
it inhibits astrogliosis improving the microenvironment to SC repair [27].
In addition, rapamycin is an immunosuppressant that inhibits the mTor pathway 
selectively, and, it is considered neuroprotective because it increases the anti-
inflammatory microenvironment and reduces locomotor impairment and damage 
in neural tissue. Other outcomes have shown that reduced infiltrations of macro-
phages and neutrophils at the SCI also reduce microglial activation and secretion of 
TNFβ; the amount of cells expressing GFAP inhibits proliferation of astrocytes and 
promotes angiogenesis and neuronal survival around the injury [2, 30].
Finally, TGFβ is involved in GS formation process, increasing the expression of 
neurocan, a CSPG that mediates GS formation and inhibits axon growth. Therefore, 
the use of antibodies against TGFβ1 and TGFβ2 is necessary; they mitigate the 
response of GFAP, causing the interruption of scar tissue and glial membrane 
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formation that limit the edge of the injury. Astrocytes, OPCs, and NG2+ responses 
are diminished. This is possible by interrupting the Smad 3 signaling pathway in 
conjunction with TGFβ [2, 84].
In contrast, a study carried out by Kohta and colleagues showed that the inhibition 
of  TGFβ1 with a neutralizing antibody resulted in the suppression of the GS forma-
tion resulting in a mild improvement of growth and/or preservation of axons in the 
injured GS caudal to the site of contusion [31]. Furthermore, rats treated with anti-
TGFβ1 increased the activation of the microglia after injury, apparently providing a 
beneficial environment for the restoration and healing of the neural network [31].
The macrophages are immune cells with phagocytic capabilities. There are 
three subgroups, but now the focus goes towards M2 macrophages. When M2 
macrophages infiltrate the SC, they may also secrete protective factors, such as the 
anti-inflammatory cytokine IL-10, and boosting the release of protective molecules 
would be advantageous. In addition, when MMP-2 is upregulated, it represents a 
beneficial effect for SCI recovery; however, when there is a deficiency in MMP-2-
expression, an exacerbated lesion expansion, scar formation, vascular instability, 
and locomotor deficits are present [18, 85].
6.2 Cell therapies
6.2.1 Schwann cells
The SCs are the principal glia of the peripheral nervous system (PNS) [86], and 
in a SCI, they have shown to promote axonal regeneration through the formation 
of bridges across the injury. This bridge is a multicellular structure that crosses the 
lesion from the rostral to caudal part, providing an environment in which axons can 
grow and cover the GS to suppress axonal regeneration impediment [87, 88].
SC transplant provides a neuroprotective effect, preventing neural death by 
continuous inflammatory reaction caused by a SCI; moreover the neural peripheral 
grafts promote the expression of neurotrophins like BDNF and NGF, which is key 
for a successful regeneration as it delays the formation of the GS [89]. It is not advis-
able to transplant the SCs alone, because their regenerative capacity is limited by the 
secretion of myelin-associated and axonal growth inhibitors (CSPGs, semaphorins, 
and myelin-associated proteins) by the GS. Although many types of cells have been 
studied for transplantation, the SCs have always been considered as one of the best 
proposals for this treatment; however, they need to be co-transplanted with other 
molecules or cells such as OECs, MSCs, and NSCs, among other cells, in order to 
achieve its full therapeutic potential [88, 90].
6.2.2 Bone marrow mesenchymal stem cells
Bone marrow stem cells (BMSCs) are the most abundant cells in the bone mar-
row; they are hematopoietic and functional support cells [91]. The implantation 
of BMSCs has shown to have regenerative and immunomodulative properties that 
help to prevent the GS formation [91]. Furthermore, these cells are able to regulate 
CNTF-STAT3 signal transduction which reduces tissue scarring, inflammatory 
responses, and apoptosis [92]. Okuda et al. reported that BMSC sheets suppress the 
GS and provide a positive environment for axonal regeneration, causing changes in 
reactive astrocyte morphology [93]. Moreover, BMSCs can secrete different trophic 
factors (VEGF, BDNF, NGF, and hepatocyte growth factor) which increase positive 
results associated with BMSC transplantation [91, 94]. In addition, the transplant 
of BMSCs are associated with significant increases in IL-4 and IL-13; these changes 
were associated with less scar tissue formation [79].
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With all that said, BMSCs possess many features that make them eligible for cell 
culture transplantation; however there are still many knowledge gaps that need to 
be studied, such as their survival rate when transplanted.
6.2.3 Olfactory ensheathing cells
Olfactory ensheathing cells (OECs) form the glial component of the primary 
olfactory system, and they reside both on CNS and PNS [87, 95]. Recent olfactory bulb 
(OB) transplants have shown to be able to infiltrate the scar tissue, through the envi-
ronment of astrocytes thanks to their heparin profile [87]. They also provide a scaffold 
that promotes neuronal growth and angiogenesis and supply a bridge through the 
injury site that decreases the contusion area [96, 97]. OECs promote neural regenera-
tion by promoting cell-to-cell interaction with sensorial axons and migrate ahead to 
the olfactory bulb, creating a favorable environment for axonal growth where cellular 
debris are phagocytized to increase restoration, neuroinflammation is modulated, 
neuroprotection is provided, and the expression of neurotrophic factors like BNDF, 
GDNF, NGF, and ECM molecules is augmented to provide a substrate for newly 
generated axons [98, 99]. These cells inhibits pro-inflammatory cytokines and induces 
the activation anti-inflammatory cytokines; they can activate neurotrophic factors.
Neurotrophic factors secreted by OECs are capable of inhibiting scar formation 
and promote axonal regeneration, implying that they also are neuroprotective. The 
receptors of each neurotrophic factor are NGF/p75, BDNF/Trκβ, GDNF/GFR-1, 
NTN/GFR-2, and NRG-1/ErbB [43]. Also OECs reduce the expression of GFAP by 
an earlier shorter immune response by astrocytes and microglia, due to the attenua-
tion of NF-κβ, which is involved in RAs [100].
6.3 Chondroitinase ABC
The chondroitinase ABC (ChABC) is a bacterial enzyme that catalyzes the 
removal of the CSPG and therefore digests them. The administration of ChABC 
has demonstrated to inhibit CSPG and deactivate their glycosaminoglycan chains, 
which promotes a significant regeneration of axons, and M2 macrophage phenotype 
activation [2, 101].
Certain studies have used ChABC in SCI models in rats to enzymatically 
degrade CSPGs and therefore reduce its inhibitory functions in axonal regenera-
tion [35, 36]. The results of these experiments showed a significant improvement 
in locomotor and proprioceptive functions, demonstrating that the degradation of 
CSPGs is a promising strategy to avoid its long-term prejudicial effects in chronic 
SCI [36, 37]. It is also reported that the combination of glial-derived neurotrophic 
factor (GDNF) and transplanted SCs causes a reduction in astrogliosis (GFAP 
and CSPG) and is also responsible for promoting axon regeneration after SCI 
[102]. Another combination therapy with ChABC, acidic fibroblast growth factor 
(aFGF), and peripheral nerve graft bridge supports axon regeneration and func-
tional recovery after chronic SCI like so bladder physiology outcomes associated 
with an invasive repair strategy. CSPG are significantly downregulated by the 
astroglial NF-kB inhibition [83]. Taken all together, these studies demonstrate that 
the degradation of CSPGs is a promising strategy to avoid its long-term prejudicial 
effects in chronic SCI.
6.4 Iron chelators to inhibit collagen biosynthesis
Using iron chelators to inhibit collagen biosynthesis has been demonstrated to 
have beneficial effects by transient suppressing fibrous scarring in an acute SCI 
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model [45, 77]. The iron chelation of α,α’-dipyridyl (DPY) has previously shown to 
decrease the collagen synthesis at a posttranscriptional level by inhibiting 4-prolyl 
hydroxylase, one of the key enzymes in collagen metabolism [103].
In a study with unilateral SC transection in adult and postnatal mice (14 days 
old) where DPY was applied at the injury site, it was observed that collagen type 
IV deposits and axons showed the expression of tyrosine hydroxylase and these 
axons extended through the site of injury by reinnervating the striatum [104]. 
Conversely, iron chelators suppress GS but do not degrade the existing scar, 
meaning that this treatment is not transferable to chronic SCI where a mature 
lesion scar is present, with a plethora of axon growth-inhibitory molecules 
attached [105, 106].
6.5 Surgical resections
Some studies have shown that the surgical removal of the GS promotes the 
development of axons in the injured portion of the SC, suggesting that axonal 
reconnection is feasible [16, 107]. Another study indicates that the use of surgical 
resection of the GS by itself does not offer positive results, because at the time of 
incising and removing the tissue healing, the same mechanisms that are activated 
during the acute phase are reactivated, generating a second lesion [75].
On the other hand, one study showed that careful surgical resection of the scar 
and filling cavity with biocompatible matrices promotes a functional improvement 
in a full-section model [16].
Therefore, the treatment of SCI can be improved if the behavior of the GS with 
the combination of transplants [75], iron chelators [45, 77], and matrices is bio-
compatible [16]. Furthermore, Rodriguez and colleagues explored whether INDP 
in combination with scar removal and DPY provided an appropriate microenviron-
ment to promote neural restoration in chronic SCI. They found an increased activity 
in genes encoding for IL4, TGFβ, BDNF, IGF1, and GAP43, as well as a decreased 
activity in genes encoding for TNFα and IFNγ. Moreover, there was a significant 
increment in the number of serotonergic (5-HT-positive) and catecholaminergic 
(TH-positive) fibers at the caudal segment of the GS [78].
7. Conclusions
Cytokines are incredibly involved in GS formation during the acute and 
chronic phases of SCI, participating in either beneficial or detrimental effects. To 
achieve the best possible results, it is necessary to maintain the anti-inflamma-
tory microenvironment for more extended periods of time in order to promote 
axonal regeneration, M2 phenotype macrophage activation, and secretion of 
neurotrophic factors that are capable of inhibiting the GS formation in the 
chronic phase. Several clinical trials have shown different therapeutic strate-
gies to modulate the formation of GS. Although those experiments have had a 
significant therapeutic potential in patients with SCI, there are still enormous 
knowledge gaps which need further investigation in order to develop a potential 
cure for SCI.
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